Combination Therapy Development and Data Sources for Assessing Drug Contributions Roundtable
Thursday, March 14, 2019
9:00 AM EDT – 3:00 PM EDT
Thanks to all who attended! Click HERE for access to the meeting whitepaper.
Friends of Cancer Research (Friends) is proud to convene a public roundtable involving multiple stakeholders across industry, FDA, academics, research, and advocacy organizations to discuss the future of combination therapy development. Oncology drug and biologics development is increasingly evaluating combinations of two or more drugs. This can include combinations of investigational drugs, an investigational drug with a previously approved drug for a different indication, or two (or more) previously approved drugs for a different indication as novel combination therapies.
Precisely isolating effects of each component within a combination therapy by direct comparison can lead to increased trial size and duration, more operational complexity, and potentially repetitive generation of data. This can sometimes lead to difficulty recruiting patients and can result in patients being exposed to a less efficacious drug in a single agent arm.
Opportunities to streamline combination therapy development programs, which may include the use of alternative data sources, will be explored. Friends is seeking feedback from a variety of stakeholders at the roundtable.
This is a public meeting and seating is limited. Advanced registration is required. To register, please contact Mark Stewart at email@example.com or (202) 944-6700.